Skip to main content

Immunotherapy

Combining Immunotherapy and Radiotherapy Shows Good Synergy

February 2018, Vol 8, No 2

Immunotherapy: Managing Severe Treatment-Related Toxicities

January 2018, Vol 8, No 1

Opdivo First Immunotherapy Approved for Hepatocellular Carcinoma

Immunotherapy, FDA Approvals, News & Updates

December 2017, Vol 7, No 12

When Does Immunotherapy Work Best in Lung Cancer?

By Wayne Kuznar

Immunotherapy, Lung Cancer

September 2017, Vol 7, No 9

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

By Eileen Koutnik-Fotopoulos

ASCO 2017 Highlights, Immunotherapy

July 2017, Vol 7, No 7

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›

NCCN Updated Lung Cancer Guidelines Focus on Immunotherapy

July 2017, Vol 7, No 7

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

July 2017, Vol 7, No 7

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

By Phoebe Starr

June 2017, Vol 7, No 6

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

May 2017, Vol 7, No 5

Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab

May 2017, Vol 7, No 5

Page 5 of 6